Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Schizophrenia is commonly associated with impairments in pre-attentive change detection, as represented by reduced mismatch negativity (MMN). While the neurochemical basis of MMN has been linked to N-methyl-d-aspartic acid (NMDA) receptor function, the roles of the dopaminergic and/or the serotonergic systems are not fully explored in humans.
The aim of the present study was to investigate the effects of acutely depleting dopamine (DA) and serotonin (5-hydroxytryptamine, 5-HT) alone or simultaneously by depleting their amino acid precursors on MMN in healthy participants.
Sixteen healthy male subjects participated in a double-blind, placebo-controlled, cross-over design in which each subject’s duration MMN was assessed under four acute treatment conditions separated by a 5-day washout period: balanced amino acid control (no depletion), tyrosine/phenylalanine depletion (to reduce DA neurotransmission), tryptophan depletion (to reduce 5-HT neurotransmission) and tryptophan/tyrosine/phenylalanine depletion (to reduce DA and 5-HT neurotransmission simultaneously).
Acute depletion of either DA and 5-HT alone or simultaneously had no effect on MMN.
These findings suggest that modulation of the dopaminergic and serotonergic systems acutely does not lead to changes in MMN.
- Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants
Volume 208, Issue 2 , pp 233-244
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Mismatch negativity
- Tryptophan depletion
- Tyrosine depletion
- Change detection
- Industry Sectors
- Author Affiliations
- 1. Brain Sciences Institute, Faculty of Life and Social Sciences, Swinburne University of Technology, P.O. Box 218, John Street Hawthorn, 3122, Melbourne, VIC, Australia
- 2. Department of Psychology, Faculty of Health and Behavioural Sciences, University of Wollongong, Wollongong, NSW, Australia
- 3. Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA
- 4. Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, UK
- 5. School of Psychology, Psychiatry and Psychological Medicine, Monash University, Clayton, VIC, Australia
- 6. Clinical Unit Cambridge, GlaxoSmithKline, London, UK